Dyne Therapeutics Inc. Common Stock vs Fastly Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while Fastly Inc trades at $24.52 (market cap $4.32B). The key difference: Fastly Inc is the larger of the two by market cap, and Fastly Inc is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Fastly Inc for 26 Days on average.
| DYN | FSLY | |
|---|---|---|
Market Cap | $2.86B | $4.32B |
Volume | 3,341,579 | 5,665,889 |
Sector | Health | Technology |
52-Week High | $26.78 | $33.50 |
52-Week Low | $14.60 | $7.86 |
Typical Hold Time | 0 Days | 26 Days |
Enterprise Value | $2.18B | $4.38B |
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Fastly (FSLY) trades at $25.00, down 5.41% over the past day, with a bullish technical signal from moving averages and support at $25. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.15 exceeding expectations, while revenue growth is robust at 23% year-over-year. However, net income remains negative, and cash flow trends show volatility, with a net outflow of $105.61 million in 2025. Recent news highlights insider selling by the CTO but also positive coverage of AI-driven growth potential.
The outlook for FSLY is mixed, with opportunities from AI infrastructure demand and revenue targets up to $1.3 billion by 2029, but risks include persistent losses, high valuation multiples, and competitive pressures. Analyst consensus is a 'Hold' with a $28.33 price target, suggesting limited near-term upside from current levels amid execution challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →